| Document |
Document Title |
|
WO/2024/080361A1 |
The present invention relates to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. The compound of the invention has excellent α1A adrenergic receptor agonist activity and is useful as a proph...
|
|
WO/2024/079351A1 |
The present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof. The invention further relates to the use of the compounds of the invention as neuroprotective and/or neurore...
|
|
WO/2024/078871A1 |
The invention relates to the technical field of plant protection agents, in particular that of herbicides for controlling weeds and/or weed grasses in crops and in ornamental gardening and for generally controlling weeds and weed grasses...
|
|
WO/2024/078569A1 |
The present invention relates to an aromatic amide derivative, a preparation method therefor, and a use of a pharmaceutical composition comprising same in medicine. Specifically, the present invention relates to an aromatic amide derivat...
|
|
WO/2024/081603A1 |
The disclosure is in part directed to crystalline free base forms of N-(4-((2-methoxy-3-(1-(methyl-d/3)-1H,2,4-triazol-3-yl)pheny
l) amino)-5-(propanoyl-3,3,3-d/3)pyridin-2-yl) cyclopropane carboxamide, pharmaceutical compositions thereo...
|
|
WO/2024/081345A1 |
Novel PI3K inhibitors of the general formula (1) are described along with methods of their preparation and their use in the treatment of diseases associated with the elevation or activation of the PI3K pathway, formula (1), wherein R1 to...
|
|
WO/2024/078579A1 |
The present invention relates to an indole phthalocyanine compound, a preparation method therefor, and a use thereof in tumor diagnosis imaging. Specifically, the present invention relates to a compound having a structure represented by ...
|
|
WO/2024/080792A1 |
Provided are a compound, selected from compounds of Formula 1, enantiomers, diastereomers, solvates and hydrates thereof, and pharmaceutically acceptable salts thereof, methods of preparing the same, and use thereof.
|
|
WO/2024/081904A1 |
This disclosure provides compounds of Formula (I), Formula (II), Formula (III), and pharmaceutically acceptable salts of any of the foregoing, that inhibit PI3Kα. These compounds are useful for treating diseases such as cancer in a subj...
|
|
WO/2024/081351A1 |
Pyrrolidine main protease inhibitors are described that are effective as antiviral compounds.
|
|
WO/2024/081311A1 |
The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition or degradation of Cbl-b, and the treatment of Cbl-b-mediated disorders. Formula (I)
|
|
WO/2024/081385A1 |
Disclosed herein are compounds that are Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors having a structure according to Formula I, and compositions containing those compounds. Methods of preparing the compounds, and methods of using ...
|
|
WO/2024/077407A1 |
Disclosed in the present invention are a chiral reducing agent and a method for synthesizing chiral nicotine. The chiral reducing agent is a compound 1 or a compound 2, or a stereoisomer of the compound 1 and the compound 2. The structur...
|
|
WO/2024/080844A1 |
The present disclosure relates to a novel pyrimidine derivative, a solvate or stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including any of the foregoing as an active ingredient, t...
|
|
WO/2024/078592A1 |
The present invention relates to a compound targeting fibroblast activation protein (FAP) as shown in formula (X) and a use thereof, and further relates to a pharmaceutical composition containing the compound and a use. The compound or t...
|
|
WO/2024/080355A1 |
The present invention provides a compound represented by formula (I) [wherein, Q represented by the formula below (wherein # represents a binding site with a sulfur atom, and ● represents a binding site with Het) represents, inter alia...
|
|
WO/2024/080780A1 |
The present invention relates to an indazole derivative or a pharmaceutically acceptable salt thereof, and a composition for preventing, treating, or ameliorating cancer, comprising, as an active ingredient, the derivative or a pharmaceu...
|
|
WO/2024/077554A1 |
The present invention sets forth a ligand and a preparation method therefor, a metal complex, a catalytic hydrogen production system, and a use thereof. The ligand has the structural formula (I), R being selected from (II) or (III). By m...
|
|
WO/2024/079072A1 |
The present invention relates to a compound of formula (I) or any of its acceptable salts (I) wherein W, X, Y and Z each independently represents =CH- or -N=, provided that at most two of W, X, Y and Z both represent a -N= group, R1 repr...
|
|
WO/2024/078513A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of a disorder, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2024/076670A2 |
The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not l...
|
|
WO/2024/075736A1 |
The present invention addresses the problem of providing a nitrogen-containing compound effective for inhibiting cancer stem cell proliferation. The problem is solved by a nitrogen-containing compound represented by general formula (I)...
|
|
WO/2024/074848A1 |
Compounds of formula (I) are disclosed: or a salt, solvate or tautomer thereof, wherein; MPL comprises a SARS-CoV-2 main protease ligand, X comprises a divalent exit vector; Xi comprises a divalent exit vector; a and b are independently ...
|
|
WO/2024/077059A1 |
Described herein are crystalline forms of (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy-d2)-3'-flu
oro-2'-(3-(2-hydroxypropan-2-yl)-1H-pyrazol-1-yl)-5',6-dimet
hyl-2H-[1,4'-bipyridin]-2-one (compound 1), or a pharmaceutically accepta...
|
|
WO/2024/073871A1 |
It provides compounds of Formula I, a tautomer thereof, a deuterated derivative of the compound or the tautomer, and a pharmaceutically acceptable salt of the foregoing. It also provides compositions comprising the compounds of Formula I...
|
|
WO/2024/076891A1 |
Disclosed herein are compounds of Formula (IV), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (IV...
|
|
WO/2024/074641A1 |
The present invention relates to a method for preparing of an amide of the formula (I-1) or a diamide of the formula (I-2) where the variables areas defined in the claims and the description, by reacting an ester with an aromatic or hete...
|
|
WO/2024/076672A1 |
The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not l...
|
|
WO/2024/074611A1 |
The present invention relates to compounds of formula (I) and salts, stereoisomers, atrop-isomers, rotamers, tautomers or N- oxides thereof that are useful as PRMT5 inhibitors. The present invention further relates to the compounds of fo...
|
|
WO/2024/077057A1 |
Compounds having activity as kinase inhibitors are provided. The compounds have Structure (I), or a stereoisomer, tautomer, or salt thereof, wherein, R1, R3, and m are as defined herein. Methods associated with preparation and use of suc...
|
|
WO/2024/073845A1 |
The present application relates to methods for expanding hematopoietic stem cells (HSC) and/or hematopoietic progenitor cells (HPC) ex vivo and/or in vivo. The methods comprise culturing the HSCs and/or HPCs in the presence of a selectiv...
|
|
WO/2024/075815A1 |
The present invention addresses the problem of providing a cMLCK activator which can enhance myocardial contraction without the need to increase the concentration of calcium in cells. The problem is solved by a cMLCK activator comprising...
|
|
WO/2024/075051A1 |
Described herein are compounds of Formula I, wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD an...
|
|
WO/2024/076731A1 |
The present invention provides compositions and methods for treating hidradenitis suppurativa (HS) or an apocrine gland infection. In one embodiment, the invention provides a method for treating HS or an apocrine gland infection in a sub...
|
|
WO/2024/075070A2 |
The present invention relates to a compound represented by chemical formula 1 as an SOS1 inhibitor, optical isomers thereof, stereoisomers thereof, solvates thereof, isotopic variants thereof, tautomers thereof, or pharmaceutically accep...
|
|
WO/2024/076674A1 |
The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not l...
|
|
WO/2024/077244A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2024/076677A2 |
Disclosed herein are imidazolyl-alkoxyquinolin-2-amines, pharmaceutical compositions comprising such compounds, and methods of using the compounds and compositions for treating or preventing inappropriate activation of a type I interfero...
|
|
WO/2024/074127A1 |
Provided compounds of Formula (I), a tautomer thereof, a deuterated derivative of the compound or the tautomer, and a pharmaceutically acceptable salt of the foregoing, compositions comprising the compounds of Formula (I), a tautomer the...
|
|
WO/2024/074414A1 |
The present invention relates to compounds of Formula (I), (I) or an agronomically acceptable salt of said compounds wherein Q, R2, R3 and U are as defined herein. The invention further relates to herbicidal compositions which comprise a...
|
|
WO/2024/076155A1 |
The present invention evaluated a method for producing a novel ENL/AF9 YEATS domain inhibitor, wherein the ENL/AF9 YEATS domain inhibition ability of a compound made through the production method was evaluated, and the novel compound was...
|
|
WO/2024/068656A1 |
A fungicidal composition comprising a mixture of components (A) and (B), wherein components (A) and (B) are as defined in claim 1, and use of the compositions in agriculture or horticulture for controlling or preventing infestation of pl...
|
|
WO/2024/067819A1 |
A piperidine-containing polycyclic derivative modulator, a preparation method therefor, and use thereof. In particular, the present invention relates to a compound represented by general formula (II-a), a preparation method therefor, a p...
|
|
WO/2024/066986A1 |
The present invention relates to a 2-aminopyrimidine compound, and a use and pharmaceutical composition thereof. The compound can inhibit CDK4 and CDK6 activity, in particular CDK4 activity with high selectivity, and treat or prevent hyp...
|
|
WO/2024/073475A1 |
Described herein are compounds of Formula II or conjugates of Formula II' and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents or degraders for certain p...
|
|
WO/2024/068950A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2024/067709A1 |
Provided are a compound (I) or a pharmaceutically acceptable salt thereof, an ester thereof, an optical isomer thereof, a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, an N-oxide thereof, an isotopical...
|
|
WO/2024/067675A1 |
The present invention provides a compound represented by formula (I), a pharmaceutical composition, and a preparation method therefor and use thereof. The compound has a good inhibitory effect on KIF18A, and can be used alone or in a bin...
|
|
WO/2024/071439A1 |
The present invention provides a novel compound that has an STAT6 inhibitory effect and is efficacious in treating inflammatory diseases and allergic diseases such as atopic dermatitis. A compound represented by general formula (I) and h...
|
|
WO/2024/067818A1 |
The present disclosure relates to a chimeric compound used for targeted degradation of a BCL-2 protein, a preparation method therefor, and pharmaceutical application thereof. Specifically, the present disclosure relates to a heterocyclic...
|
